Analyst firms · UBS · EW

UBS EW price target and rating history

Edwards Lifesciences Corporation (EW) · Health Care

UBS rates Edwards Lifesciences Corporation (EW) Buy with a $110 price target, as of its latest action on Jul 28, 2026. It has published 5 rating actions on EW since July 2021, including 1 upgrade and 0 downgrades. Across 7 firms with a EW price target in the last 12 months, the median target is $110. UBS's target matches it.

Current rating
Buy
Price target
$110
Median target, all firms
$110
Actions on EW
5

UBS price target on EW

$126$105$8420222023202420252026
UBS price target on EW, each point a stated target, July 2021 to July 2026.

Every UBS rating on EW

How other firms rate EW

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Robert W. BairdOutperform$116Nov 5, 2026
Truist SecuritiesBuy$113Nov 4, 2026
BarclaysOverweight$110Oct 7, 2026
UBSBuy$110Jul 28, 2026
Leerink PartnersOutperform$101Jul 24, 2026
Wolfe ResearchOutperform$92Apr 1, 2026
TD CowenBuy$97Jan 9, 2026

Questions about UBS and EW

What is UBS's price target for EW?
UBS's latest stated price target for Edwards Lifesciences Corporation (EW) is $110, from its action on Jul 28, 2026.
What is UBS's rating on EW?
UBS rates EW Buy, a bullish rating, as of Jul 28, 2026.
When did UBS last change its view on EW?
On Jul 28, 2026, UBS starts coverage at Buy, price target $110.
How does UBS's EW target compare with other analysts?
Across 7 firms with a EW price target in the last 12 months, the median target is $110. UBS's target matches it.

More EW rating histories

All UBS ratingsEW news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.